Cyclerion Therapeutics Files 8-K on Material Agreement
Ticker: CYCN · Form: 8-K · Filed: Mar 25, 2025 · CIK: 1755237
| Field | Detail |
|---|---|
| Company | Cyclerion Therapeutics, Inc. (CYCN) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
Cyclerion Therapeutics filed an 8-K on 3/21/25 covering a material agreement and equity sales.
AI Summary
On March 21, 2025, Cyclerion Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity securities and includes financial statements and exhibits. The company is incorporated in Massachusetts and its principal executive offices are located in Cambridge.
Why It Matters
This filing indicates significant corporate actions and potential financial transactions for Cyclerion Therapeutics, Inc., requiring investor attention.
Risk Assessment
Risk Level: medium — The filing mentions material definitive agreements and unregistered sales of equity, which can indicate significant corporate events and potential dilution or financial restructuring.
Key Numbers
- 001-38787 — SEC File Number (Identifies the company's filing with the SEC.)
- 83-1895370 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Cyclerion Therapeutics, Inc. (company) — Registrant
- Massachusetts (location) — State of Incorporation
- Cambridge (location) — City of Principal Executive Offices
- March 21, 2025 (date) — Date of Report
FAQ
What is the nature of the material definitive agreement mentioned in the 8-K filing?
The 8-K filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.
What type of equity securities were sold unregistered?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the type or amount of securities sold in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on March 21, 2025.
What is Cyclerion Therapeutics, Inc.'s standard industrial classification?
Cyclerion Therapeutics, Inc.'s standard industrial classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where are Cyclerion Therapeutics, Inc.'s principal executive offices located?
Cyclerion Therapeutics, Inc.'s principal executive offices are located at 245 First Street, 18th Floor, Cambridge, Massachusetts, 02142.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 25, 2025 regarding Cyclerion Therapeutics, Inc. (CYCN).